Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Takeaways: Health Canada’s software update effectively turns MiniMed 780G into a more flexible, next‑gen automated insulin delivery platform in Canada, now covering adults with t...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
Takeaways: AbbVie is doubling down on Canada as a discovery hub by becoming the founding sponsor of BioLabs University of Toronto, a ~40,000 sq. ft shared lab at MaRS t...
Takeaways: Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunolo...
Takeaways VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increa...
Takeaways: Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...
Takeaways: Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among ...
Takeaways: AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
